849928-34-3

Basic information

• Product Name: 1-CBZ-2-METHYL-PIPERIDIN-4-ONE
• Synonyms: 1-N-CBZ-2-METHYL-PIPERIDIN-4-ONE;1-CBZ-2-METHYL-PIPERIDIN-4-ONE;1-Benzyloxycarbonyl-2-methylpiperidin-4-one;2-Methyl-4-oxopiperidine-1-carboxylic acid benzyl ester;benzyl 2-Methyl-4-oxopiperidine-1-carboxylate;1-Cbz-2-Methyl-4-oxopiperidine;N-1-Cbz-2-methyl piperidin-4-one;EOS-60474
• CAS NO: 849928-34-3
• Molecular Formula: C₁₄H₁₇NO₃
• Molecular Weight: 247.29
• Mol File: 849928-34-3.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 388.066 °C at 760 mmHg
• Flash Point: 188.496 °C
• Appearance: /
• Density: 1.164
• Storage Temp.: 2-8°C
• PKA: -1.57±0.40(Predicted)
• CAS DataBase Reference: 1-CBZ-2-METHYL-PIPERIDIN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-CBZ-2-METHYL-PIPERIDIN-4-ONE(849928-34-3)
• EPA Substance Registry System: 1-CBZ-2-METHYL-PIPERIDIN-4-ONE(849928-34-3)

Safety Data

• Hazardous Substances Data: 849928-34-3(Hazardous Substances Data)

Usage

General Description

1-CBZ-2-METHYL-PIPERIDIN-4-ONE is a chemical compound with the molecular formula C12H17NO2. It is a derivative of piperidin-4-one and a member of the carbamate family. 1-CBZ-2-METHYL-PIPERIDIN-4-ONE is used in organic synthesis and pharmaceutical research as a building block for the synthesis of various bioactive compounds. It is known for its role in the production of pharmaceutical drugs and as a precursor for the synthesis of other chemical compounds with potential therapeutic properties. Additionally, it is used in the research and development of new drugs and in the study of the structure-activity relationships of bioactive molecules.

Upstream product

• 190906-91-3 3,4-dihydro-2-methyl-4-oxo-1(2H)-pyridinecarboxylic acid phenylmethyl ester 
• 620-08-6 4-methoxypyridine 
• 75-24-1 trimethylaluminum 
• 185847-84-1 benzyl 4-oxo-3,4-dihydropyridine-1(2H)-carboxylate 
• 501-53-1 benzyl chloroformate 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 71322-99-1 2-methyl-4-oxopiperidine 
• 852051-10-6 (R)-1-benzyloxycarbonyl-2-methyl-4-piperidone 
• 921599-74-8 benzyl (2S)-2-methyl-4-oxopiperidine-1-carboxylate 
• 190906-92-4 tert-butyl 2-methyl-4-oxopiperidine-1-carboxylate 
• 1146733-34-7 benzyl 4-[2-(5-methoxy-2-nitro-phenyl)-ethylamino]-2-methyl-piperidine-1-carboxylate 
• 1227685-18-8 benzyl (2S,4S)-4-hydroxy-2-methyl-4-(trichloromethyl)-piperidine-1-carboxylate 
• 1227685-41-7 (2S,4R)-1-benzyl 4-methyl 4-(3-fluorophenylamino)-2-methylpiperidine-1,4-dicarboxylate 
• 1227685-11-1 benzyl (2S,4R)-4-cyano-4-[(3-ethoxy-3-oxopropanoyl)(3-fluorophenyl)amino]-2-methylpiperidine-1-carboxylate 
• 1227685-13-3 benzyl (5R,7S)-1-(3-fluorophenyl)-4-hydroxy-7-methyl-2-oxo-1,8-diazaspiro[4.5]decane-8-carboxylate 
• 1227685-14-4 (5R,7S)-benzyl 1-(3-fluorophenyl)-7-methyl-2-oxo-1,8-diazaspiro[4.5]dec-3-ene-8-carboxylate 
• 1416161-82-4 1-benzyl 4-methyl (2S,4R)-4-[(3-ethoxy-3-oxopropanoyl)(3-fluorophenyl)amino]-2-methylpiperidine-1,4-dicarboxylate 
• 1416161-83-5 8-benzyl 3-ethyl (5R,7S)-1-(3-fluorophenyl)-7-methyl-2,4-dioxo-1,8-diazaspiro[4.5]decane-3,8-dicarboxylate 
• 1416161-72-2 (5R,7S)-1-(3-fluorophenyl)-8-[4-hydroxy-3-(5-methyl-1H-pyrazol-1-yl)benzyl]-7-methyl-1,8-diazaspiro[4.5]dec-3-en-2-one 

Relevant articles and documents

Highly Enantioselective Catalytic Addition of Grignard Reagents to N-Heterocyclic Acceptors

General methods to prepare chiral N-heterocyclic molecular scaffolds are greatly sought after because of their significance in medicinal chemistry. Described here is the first general catalytic methodology to access a wide variety of chiral 2- and 4-substituted tetrahydro-quinolones, dihydro-4-pyridones, and piperidones with excellent yields and enantioselectivities, utilizing a single catalyst system.

Methyl-substitution of an iminohydantoin spiropiperidine β-secretase (BACE-1) inhibitor has a profound effect on its potency

The IC50 of a beta-secretase (BACE-1) lead compound was improved ～200-fold from 11 μM to 55 nM through the addition of a single methyl group. Computational chemistry, small molecule NMR, and protein crystallography capabilities were used to com

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.